How Effective are Venetoclax + Rituximab?

Last updated on: 11/7/2024

Venetoclax + Rituximab Response as Second Line

If you are taking VenR as your second line of therapy, listed below is how likely, on average, the treatment combination will be effective for you.

Response Type	Percentage of Patients
CLL patients who achieve undetectable minimal residual disease (uMRD) in a blood sample taken three months after completing the two-year treatment	54%
CLL patients who achieve complete remission (a full reduction of CLL signs/symptoms) after treatment	8%
CLL patients who achieve partial remission (a partial reduction of CLL signs/symptoms) after treatment.	82%

On average, this is how long venetoclax + rituximab will keep CLL in remission based on CLL type (the treatment period ends after 2 years).

*At the 5-year check-in since the start of treatment, 72.7% of mutated IGHV patients continued to remain in remission.

The percentage of CLL patients who experience mild-moderate versions of common side effects from VenR is shown below.

Side Effect	Percentage of Patients Affected
Neutropenia	65%
Diarrhea	40%
Upper respiratory tract infection	39%
Fatigue	22%
Nausea	21%

For more information on these side effects, you can visit the Side Effects Management section of this guide.

For more information on the side effects of VenR, visit the Venclexta Medication Guide.

Click here to locate financial resources for venetoclax. For additional resources, click here to visit the financial support section of the guide.